Optovue & the AngioVue Imaging System
Retinal Consultants of Arizona is pleased to announce the addition of the AngioVue Imaging System by Optovue, Inc. to its eye test equipment.
The AngioVue system provides a new way for our doctors to visualize the presence of blood flow in the retina without the need to inject a contrast dye. RCA is one of the first practices in the United States to have access to this revolutionary imaging technology.
The AngioVue Imaging System may benefit patients who may be at risk or are being treated for macular degeneration, diabetic retinopathy, retinal vein occlusion or choroidal neovascularization.
- Capturing an image with AngioVue is quick and non-invasive, so your doctor can monitor your condition more frequently. This allows RCA to keep a close watch on eye disease and how treatment may or may not be working.
- Traditional imaging methods, such as fluorescein angiography, do not show blood flow in the micro vessels that we are able to see with AngioVue. Because AngioVue gives us a more detailed view, we can diagnose disease earlier and confirm the effects of treatment sooner.
- AngioVue lets your doctor view individual layers of the retina to look for very small changes that may ultimately affect your vision. By examining each layer of the retinal tissue, we are taking the most comprehensive approach possible to diagnosing and managing eye disease.
Optovue, Inc. is an ophthalmic device company dedicated to working with eye care professionals and clinical researchers to lead the commercialization of new imaging modalities that improve diagnosis and therapy of ocular disease.
Incorporated in December 2003, Optovue was founded to develop the next generation ophthalmic diagnosis instrument based on ultra-high speed optical coherence tomography (OCT) technology. OCT provides physicians with advanced retina diagnostic capabilities that have significant benefits for patients who have retina conditions such as macular degeneration, diabetic retinopathy, glaucoma, and other macular diseases.